hVIVO targets strong return to growth after transition year

hVIVO PLC (AIM:HVO), the AIM-listed human challenge trial specialist, expects high single-digit revenue growth in 2026, weighted to the second half, as it moves past a year of deliberate restructuring. The London-based clinical development company posted revenue of £46.8 million for the year ended 31 December, down from £62.7 million the prior year.